Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pain, Postoperative 9Breast Neoplasms 6Brain Neoplasms 6Neoplasms 4Lung Neoplasms 4Thyroid Neoplasms 3Agnosia 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Rectal Neoplasms 2Prostatic Neoplasms 2Pheochromocytoma 2Neoplasm Metastasis 2Liver Neoplasms 2Dexmedetomidine 2Colonic Neoplasms 2Chronic Pain 2Supratentorial Neoplasms 1Sleep Initiation and Maintenance Disorders 1Sigmoid Neoplasms 1Seizures 1Prostatic Hyperplasia 1Postoperative Nausea and Vomiting 1Postoperative Analgesia 1Pneumoperitoneum 1Pancreatic Neoplasms 1Pain, Intractable 1Obesity 1Neuroinflammatory Diseases 1Neurofibromatoses 1

Interventions

Ketamine 2substance P-saporin 1Infusion Pumps, Implantable 1Fentanyl 1Dexmedetomidine 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pain, Intractable × Dexmedetomidine × Clear all
NCT03936205 2019-05-14

Dexmedetomidine Addition to Morphine in Patients With Metastatic Cancer

Hotel Dieu de France Hospital

Phase 2/3 Completed
18 enrolled

Neoplasm Metastasis, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡